These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 27307383)

  • 1. Effect of antiviral treatment of chronic hepatitis C on the frequency of regulatory T cells, T-cell activation, and serum levels of TGF-beta.
    Chalupa P; Davidová A; Beran O; Arientová S; Boštík P; Kapla J; Kondělková K; Plíšek S; Holub M
    APMIS; 2016 Aug; 124(8):711-8. PubMed ID: 27307383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective study of T- and B-lymphocyte subpopulations, CD81 expression levels on B cells and regulatory CD4(+) CD25(+) CD127(low/-) FoxP3(+) T cells in patients with chronic HCV infection during pegylated interferon-alpha2a plus ribavirin treatment.
    Soldevila B; Alonso N; Martínez-Arconada MJ; Morillas RM; Planas R; Sanmartí AM; Martínez-Cáceres EM
    J Viral Hepat; 2011 Jun; 18(6):384-92. PubMed ID: 20487258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased peripheral CD4
    Langhans B; Nischalke HD; Krämer B; Hausen A; Dold L; van Heteren P; Hüneburg R; Nattermann J; Strassburg CP; Spengler U
    J Hepatol; 2017 May; 66(5):888-896. PubMed ID: 28040549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Th1/Th2 cytokines in serum on the pathogenesis of chronic hepatitis C and the outcome of interferon therapy.
    Zhang L; Hao CQ; Miao L; Dou XG
    Genet Mol Res; 2014 Nov; 13(4):9747-55. PubMed ID: 25501184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in T-cell subsets in HIV-HCV-coinfected patients during pegylated interferon-alpha2a plus ribavirin treatment.
    Massanella M; Tural C; Papagno L; Garcia E; Jou A; Bofill M; Autran B; Clotet B; Blanco J
    Antivir Ther; 2010; 15(3):333-42. PubMed ID: 20516553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy.
    Yu ML; Chuang WL; Dai CY; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Tsai SL; Kuo HT
    Transl Res; 2006 Sep; 148(3):120-7. PubMed ID: 16938649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct-acting antiviral therapy enhances total CD4+ and CD8+ T-cells responses, but does not alter T-cells activation among HCV mono-infected, and HCV/HIV-1 co-infected patients.
    Najafi Fard S; Schietroma I; Corano Scheri G; Giustini N; Serafino S; Cavallari EN; Pinacchio C; De Girolamo G; Ceccarelli G; Scagnolari C; Vullo V; d'Ettorre G
    Clin Res Hepatol Gastroenterol; 2018 Sep; 42(4):319-329. PubMed ID: 29279268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of IL-10-secreting CD8
    Wang W; Tong Z; Zhong J; Zhang L; Zhang H; Su Y; Gao B; Zhang C
    Immunol Lett; 2018 Oct; 202():16-22. PubMed ID: 30055200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum tumour necrosis factor-alpha and transforming growth factor-beta levels in chronic hepatitis C patients are immunomodulated by therapy.
    Neuman MG; Benhamou JP; Bourliere M; Ibrahim A; Malkiewicz I; Asselah T; Martinot-Peignoux M; Shear NH; Katz GG; Akremi R; Benali S; Boyer N; Lecomte L; Le Breton V; Le Guludec G; Marcellin P
    Cytokine; 2002 Jan; 17(2):108-17. PubMed ID: 11886178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T cell receptor excision circles (TRECs), CD4+, CD8+, and their CD45RO+, and CD45RA+, subpopulations in hepatitis C virus (HCV)-HIV-co-infected patients during treatment with interferon alpha plus ribavirin: analysis in a population on effective antiretroviral therapy.
    Arizcorreta A; Márquez M; Fernández-Gutiérrez C; Guzmán EP; Brun F; Rodríguez-Iglesias M; Girón-González JA
    Clin Exp Immunol; 2006 Nov; 146(2):270-7. PubMed ID: 17034579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral loss of CD8(+) CD161(++) TCRVα7·2(+) mucosal-associated invariant T cells in chronic hepatitis C virus-infected patients.
    Barathan M; Mohamed R; Vadivelu J; Chang LY; Saeidi A; Yong YK; Ravishankar Ram M; Gopal K; Velu V; Larsson M; Shankar EM
    Eur J Clin Invest; 2016 Feb; 46(2):170-80. PubMed ID: 26681320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Helper T cell cytokine response to ribavirin priming before combined treatment with interferon alpha and ribavirin for patients with chronic hepatitis C.
    Furusyo N; Kubo N; Toyoda K; Takeoka H; Nabeshima S; Murata M; Nakamuta M; Hayashi J
    Antiviral Res; 2005 Jul; 67(1):46-54. PubMed ID: 15913800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of clinical and virologic responses to antiviral treatment and regulatory T cell evolution in patients with hepatitis C virus-induced mixed cryoglobulinemia vasculitis.
    Landau DA; Rosenzwajg M; Saadoun D; Trébeden-Negre H; Klatzmann D; Cacoub P
    Arthritis Rheum; 2008 Sep; 58(9):2897-907. PubMed ID: 18759287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toll-Like Receptor 2 Modulates the Balance of Regulatory T Cells and T Helper 17 Cells in Chronic Hepatitis C.
    Liu X; Guan JH; Jiang BC; Li ZS; Zhu GZ
    Viral Immunol; 2016; 29(6):322-31. PubMed ID: 27082819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between regulatory T cells and the combination of pegylated interferon and ribavirin for the treatment of chronic hepatitis type C.
    Akiyama M; Ichikawa T; Miyaaki H; Motoyoshi Y; Takeshita S; Ozawa E; Miuma S; Shibata H; Taura N; Nakao K
    Intervirology; 2010; 53(3):154-60. PubMed ID: 20068349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Dynamic changes in programmed death-1 expression on the surface of T cells in chronic hepatitis C patients undergoing interferon therapy].
    Dong RQ; Zhou DF; Han R; Zhou JY; Zhao CY; Zhen Z
    Zhonghua Gan Zang Bing Za Zhi; 2013 Dec; 21(12):899-902. PubMed ID: 24636290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum apolipoprotein B-100 concentration predicts the virological response to pegylated interferon plus ribavirin combination therapy in patients infected with chronic hepatitis C virus genotype 1b.
    Yoshizawa K; Abe H; Aida Y; Ishiguro H; Ika M; Shimada N; Tsubota A; Aizawa Y
    J Med Virol; 2013 Jul; 85(7):1180-90. PubMed ID: 23918536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HCV-specific CD8+ cell detection at week 12 of chronic hepatitis C treatment with PEG-interferon-α2b/ribavirin correlates with infection resolution.
    Larrubia JR; Lokhande MU; Moreno-Cubero E; García-Garzón S; Miquel J; Parra-Cid T; González-Praetorious A; Perna C; Lázaro A; Sanz-de-Villalobos E
    Cell Immunol; 2013; 286(1-2):31-8. PubMed ID: 24287274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD81 expression for discrimination between sustained virologic response and relapse in patients with chronic hepatitis C.
    Welker MW; Hofmann WP; Lange CM; Herrmann E; Sarrazin C; Zeuzem S; Kronenberger B
    Scand J Gastroenterol; 2011 Jul; 46(7-8):973-80. PubMed ID: 21615225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased frequency of late-senescent T cells lacking CD127 in chronic hepatitis C disease.
    Barathan M; Mohamed R; Saeidi A; Vadivelu J; Chang LY; Gopal K; Ram MR; Ansari AW; Kamarulzaman A; Velu V; Larsson M; Shankar EM
    Eur J Clin Invest; 2015 May; 45(5):466-74. PubMed ID: 25721991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.